EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Stakeholder perspectives regarding single participant research in oncology

Sarah Heynemann, Wendy Lipworth, Sue-Anne McLachlan, Jennifer Philip, Tom John, Ian Kerridge

Research Ethics · 07.07.2026

DOI: 10.1177/17470161261463012 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Research Ethics, online erschienen am 07.07.2026. Verfasst von Sarah Heynemann und 5 weiteren Autor:innen. Die Arbeit nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Health and Medical Research Council.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The term ‘N-of-1 trial’ has traditionally referred to a specific, well-defined, clinical trial methodology, involving evaluation of an intervention (or interventions) in a single individual, with alternating periods ‘on’ and ‘off’ an intervention. Given methodological constraints, such trials are best suited to the study of chronic, stable conditions, and so have had a limited role in progressive conditions like cancer. According to evidence-based medicine hierarchies, conventional, randomised, N-of-1 trials are considered ‘type 1’ evidence. In recent years, however, the term ‘N-of-1 trial’ has appeared with growing frequency within the academic cancer literature but with reference to a heterogeneous range of research activities (which diverge in various ways from the conventional N-of-1 trial design). In this qualitative study, 72 semi-structured interviews were conducted with key stakeholders across the cancer clinical trials landscape to explore perspectives regarding the notion of ‘N-of-1 trials’ in oncology. This included various types of ‘trial professionals’ (trialists, statisticians, ethicists and ethics review board members, industry, regulatory and reimbursement body representatives), as well as ‘consumer representatives’. Findings of this study highlight that two broad categories of issues are particularly salient to stakeholders in relation to single participant focused research: (1) issues to do with opportunity to participate, and (2) issues to do with consent and risk management. We draw attention to implications for those engaged in the review of various forms of single participant focused research, and how these differ from considerations pertinent to more traditional clinical research. In particular, we caution against any ‘one size fits all’ approach to assessment of ‘acceptable’ risk during ethical review of such activities. Finally, we consider whether novel forms of oversight may be required, including a possible role for ethics review boards to engage directly with individuals considering participation in such studies.

Förderung

  • National Health and Medical Research Council

Zitieren

APA

Heynemann, S., Lipworth, W., McLachlan, S., Philip, J., John, T., & Kerridge, I. (2026). Stakeholder perspectives regarding single participant research in oncology. Research Ethics. https://doi.org/10.1177/17470161261463012

Vancouver

Heynemann S, Lipworth W, McLachlan S, Philip J, John T, Kerridge I. Stakeholder perspectives regarding single participant research in oncology. Research Ethics. 2026. doi:10.1177/17470161261463012

BibTeX
@article{Heynemann2026,
  author = {Heynemann, Sarah and Lipworth, Wendy and McLachlan, Sue-Anne and Philip, Jennifer and John, Tom and Kerridge, Ian},
  title = {Stakeholder perspectives regarding single participant research in oncology},
  journal = {Research Ethics},
  year = {2026},
  doi = {10.1177/17470161261463012}
}
Kostenlos starten →